Biofrontera shares rise 10.81% intraday after completing Phase 1 pharmacokinetics study for Ameluz.

Biofrontera Inc. (NASDAQ:BFRI) surged 10.81% intraday following the announcement that it has completed the database lock for its Phase 1 pharmacokinetics study of Ameluz, a key development milestone for its skin treatment. The study, which evaluates the drug’s absorption, distribution, metabolism, and excretion, marks progress in the drug’s regulatory pathway and enhances investor confidence in its potential commercialization. The positive movement aligns with the company’s advancement in clinical research, a critical factor for biotech firms in early-stage drug development. No conflicting or unrelated news was reported during the trading period.